News & Media

Press Releases

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual …

Download a PDF: EN or FR

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners

Download a PDF copy of this press release: EN FR Funds to be used to continue clinical development of AZP-3601 for hypoparathyroidism while progressing AZP-3813 …

Download a PDF: EN or FR

Amolyt Pharma to Host Key Opinion Leader Webinar and Discuss Results of Phase I Clinical Trial of AZP-3601 on Friday, October 1st at 10:00am ET

Download a PDF copy of this press release: EN Company recently completed a Phase 1 clinical trial in healthy volunteers of AZP-3601 for the potential …

Download a PDF: EN

Presentations

  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
AZP-3813

AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor as a Potential New Treatment for Acromegaly

AZP-3601

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

AZP-3601

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

AZP-3601

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

AZP-3601

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

AZP-3601

cHP Natural History Study: ISPOR Poster

AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Upcoming events

Date: June 1, 2022

Date: June 10 – June 14, 2022 (Atlanta, Georgia)

Date: September 9 - 12, 2022 (Austin, TX)

Social Updates

TWITTER

Scroll to Top